Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Neurology & Psychiatry
Filter     Order     Display # 
Date Item Title Hits
16 Mar 2010 Desmoteplase enters clinical phase II in Japan in ischaemic stroke representing Lundbeck's first clinical programme in Japan 6
15 Mar 2010 Icagen Reports Positive Results for ICA-105665 in Patients With Photosensitive Epilepsy 5
11 Mar 2010 Allon's Phase 1 Trial Broadens Davunetide's Intranasal Safety and Dose Range 142
10 Mar 2010 BOTOX (OnabotulinumtoxinA) Receives FDA Approval for Treatment of Upper Limb Spasticity in Adults 4
10 Mar 2010 Evotec Reports Good Progress in Product Development in Treatment-Resistant Depression in its Alliance with Roche 4
10 Mar 2010 Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia 4
10 Mar 2010 Limerick BioPharma Announces Positive Phase 1a Data for LIM-0705 4
10 Mar 2010 BioAlliance Announces Positive Preliminary Results in the First Phase I Clinical Trial of fentanyl Lauriad 4
09 Mar 2010 Actelion receives FDA complete response letter for Zavesca (miglustat) for the treatment of Niemann-Pick type C disease 5
09 Mar 2010 INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray 5
09 Mar 2010 Omeros Licenses PDE7 Compounds for Parkinson's Disease Program 5
08 Mar 2010 NeuroSearch announces new findings from the MermaiHD Phase III study supporting potential disease modifying properties of Huntexil 5
08 Mar 2010 Acura Pharmaceuticals and King Pharmaceuticals Announce Positive Top Line Results of a Clinical Study Assessing Relative Abuse Potential 5
05 Mar 2010 ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS 6
03 Mar 2010 Bristol-Myers Squibb and Allergan Enter Global Agreement on Investigational Neuropathic Pain Medicine 7
03 Mar 2010 Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine) Alzheimer’s Disease Clinical Development Program 7
03 Mar 2010 PTC THERAPEUTICS AND GENZYME CORPORATION ANNOUNCE PRELIMINARY RESULTS FROM THE PHASE 2B CLINICAL TRIAL OF ATALUREN FOR NONSENSE MUTATION DUCHENNE/BECKER MUSCULAR DYSTROPHY 10
03 Mar 2010 Lundbeck and Takeda finalise plans to initiate phase III pivotal clinical trials with Lu AA21004 and Lu AA24530 7
02 Mar 2010 Icagen Reports Results of Phase Ib Pain Study of ICA-105665 6
02 Mar 2010 FDA Approves Exalgo(TM) Extended-Release Tablets 9
25 Feb 2010 Orexo Announces Kyowa Hakko Kirin’s Submission of KW-2246 (Abstral) for Approval in Japan 32
25 Feb 2010 Data from a post hoc analysis using desmoteplase in ischaemic stroke presented at the International Stroke Conference 6
25 Feb 2010 Copaxone® 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy and Safety 11
24 Feb 2010 Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial 8
24 Feb 2010 Arena Pharmaceuticals Announces FDA Acceptance of Lorcaserin NDA for Filing 7
23 Feb 2010 Catalyst Pharmaceutical Partners and The National Institute on Drug Abuse Plan to Initiate U.S. Phase II(b) Clinical Trial for Cocaine Addiction 13
23 Feb 2010 Allon Presents Peripheral Neuropathy Preclinical Efficacy Data For AL-309 13
23 Feb 2010 FDA Advisory Committee Recommends Approval Of XIFAXAN® (Rifaximin) Tablets, 550 Mg For Maintenance Of Remission Of Hepatic Encephalopathy 11
22 Feb 2010 FDA Approves Once-Daily MIRAPEX ER for the Treatment of Early Parkinson's Disease 19
22 Feb 2010 Novartis oral multiple sclerosis development compound Gilenia®* (FTY720) granted US priority review status 37
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 2288

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

Oncology Market Leaders
Order Now

Subscribe La Merie Biologics